Aerosol tribocharging and its relation to the deposition of Oxis™ Turbuhaler® in the electrical next generation impactor

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Although there have been published electrostatic characterisation studies of drug‐only Turbuhaler® and lactose carrier–drug formulations, there has not been an investigation into spheronised agglomerates containing micronised lactose and eformoterol, such as in Oxis® Turbuhaler®. Ten doses of Oxis® (12 µ g eformoterol) were dispersed into an electrical next generation impactor (eNGI) in a single run, and runs were conducted in triplicate to determine the aerosol performance and aerosol charge distribution at flow rates of 30, 60 and 90 L/min. Eformoterol fine particle fraction (FPF) reached a maximum of 50%–60% at 60 and 90 L/min, whereas lactose FPF increased from 31% to 42% when flow rate was increased from 30 to 90 L/min. Specific net charge (C/µ g) within the eNGI stages increased from 30 to 60 L/min, but then decreased at 90 L/min. These results were attributed to the shift in balance between surface charging after interparticle and particle–surface collision (dominant at 30 and 60 L/min) and charge separation after impact fragmentation of agglomerates (dominant at 90 L/min). However, the aerosol charge profiles do not suggest that electrostatic forces play a major role in the deposition of Oxis® Turbuhaler® dry powder formulation.
Original languageEnglish
Pages (from-to)5270-5280
Number of pages11
JournalJournal of Pharmaceutical Sciences
Volume100
Issue number12
DOIs
Publication statusPublished - 2011
Externally publishedYes

Keywords

  • particle size
  • pulmonary drug delivery
  • static charge
  • aerosol
  • materials science
  • dry powder inhaler
  • turbuhaler
  • eformoterol
  • lactose
  • eNGI

Fingerprint

Dive into the research topics of 'Aerosol tribocharging and its relation to the deposition of Oxis™ Turbuhaler® in the electrical next generation impactor'. Together they form a unique fingerprint.

Cite this